CTCs that fail to be captured by EpCAM‐dependent methods are detectable with antibodies directed against mesenchymal as well as other tumor markers (Raimondi et al., 2011; Schneck et al., 2015), suggesting that CTCs are indeed heterogeneous for epithelial and mesenchymal markers. Here, EPCAM is linked to neoplasm.